Genmab AS (CHIX:GMABC) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:GMABC Genmab AS CHIX:GMABC
95 GF Score
Price kr1,859.75
GF Value kr2,306.62
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Genmab AS FFO per Share?

FFO per Share only applies to REITs.

CHIX:GMABC
95GF Score
Genmab AS CHIX:GMABC
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Genmab AS (CHIX:GMABC) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued. The current stock price of kr1,859.75 is trading 19.4% below its estimated GF Value™ of kr2,306.62. GuruFocus considers Genmab AS to be Modestly Undervalued.

Key valuation signals for CHIX:GMABC:

  • FFO per Share:
  • GF Value™: kr2,306.62 vs. price of kr1,859.75 (19.4% below fair value)
  • GF Score™: 95/100 with 5 warning signs

No single metric tells the full story. See the CHIX:GMABC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
95GF Score

Get the complete analysis for CHIX:GMABC

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1,859.75
Price
kr2,306.62
GF Value